In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...
Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 million and a GIP-targeting asset intended to induce higher-quality weight ...
The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...
Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.
Veru says its muscle-maintaining drug preserved more lean mass in older patients taking a GLP-1, but skittish investors didn’t celebrate.
Veru said on Monday its experimental drug in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...
Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. The Trump ...
Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results are due in April 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback